Eli Lilly and Company LLY
NYSE
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 15.57% | 25.33% | 168.07% | 50.52% | 475.29% |
| Total Depreciation and Amortization | 15.96% | 11.72% | 9.94% | 20.71% | 0.69% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 151.81% | 572.88% | -150.22% | -64.66% | -31.06% |
| Change in Net Operating Assets | -63.99% | 70.39% | 50.54% | -65.21% | 12,426.53% |
| Cash from Operations | 29.00% | 246.29% | 220.11% | 30.34% | 138.02% |
| Capital Expenditure | -52.28% | -72.83% | -54.04% | -70.21% | -54.51% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -61.57% | -- | -- | -37,100.00% | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -1,123.70% | -2,612.41% | 71.13% | 66.10% | 86.96% |
| Cash from Investing | -178.30% | -739.48% | -16.79% | -45.87% | 25.54% |
| Total Debt Issued | -178.80% | -- | -72.53% | -100.00% | 35.08% |
| Total Debt Repaid | 100.00% | -205.82% | 59.44% | -100.01% | -32.45% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | 46.75% | -131.36% | -96.33% | 26.59% | -58.71% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -14.49% | -14.77% | -15.01% | -15.21% | -14.99% |
| Other Financing Activities | 41.38% | 87.10% | 13.85% | 45.32% | 38.69% |
| Cash from Financing | -1,459.51% | 776.79% | -351.45% | -1,176.63% | 151.30% |
| Foreign Exchange rate Adjustments | 75.00% | -118.91% | -49.24% | 84.35% | -85.90% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -163.36% | 1,196.11% | -1,034.86% | -2,388.66% | 4,312.65% |